Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model.

ABSTRACT:

Background

The options for the treatment of nonalcoholic steatohepatitis (NASH) are limited. We examined the effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on the fatty liver Shionogi (FLS)-ob/ob mice, a non-alcoholic steatohepatitis mouse model.

Methods

FLS-ob/ob male mice were treated with vehicle (n = 10) and ipragliflozin (n = 8). Serum metabolic markers, histopathology of the liver, hepatic cholesterol and triglyceride levels and hepatic mRNA levels related to fibrosis, lipid metabolism and endoplasmic reticulum (ER) stress were compared between the two groups.

Results

The body weight and hepatic cholesterol and triglyceride levels were significantly decreased in the ipragliflozin group compared with the control

SUBMITTER: Yamane M 

PROVIDER: S-EPMC6437417 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature